Critical Clarification Required
There appears to be a medication name confusion in your question. "Trileptal" is the brand name for oxcarbazepine, an antiepileptic drug, NOT bupropion. The evidence provided discusses bupropion dosing for adolescents, but your patient is on Trileptal (oxcarbazepine) 150 mg BID.
If You Mean Trileptal (Oxcarbazepine) for Epilepsy:
Continue the current dose of 150 mg twice daily (300 mg/day total) and monitor for seizure control before considering any dose adjustment. 1
Dosing Algorithm for Trileptal in Adolescents:
- Current dose: 150 mg BID (300 mg/day) is within the therapeutic range
- Effective dose range: The mean effective dose in adolescents is approximately 900 mg/day, but many patients respond to lower doses 1
- Maximum studied dose: Up to 600 mg BID (1200 mg/day) in adolescents
- Titration approach:
- If seizures are not controlled, increase by 150-300 mg/day increments every 1-2 weeks
- Target dose is typically 30 mg/kg/day, but often less is effective
- Most patients in clinical trials achieved control with <30 mg/kg/day 1
Key Monitoring Points:
- Efficacy: 91.1% of adolescents showed ≥50% seizure reduction; 59.4% became seizure-free 1
- Adverse effects: Occur in only 11.2% of patients and are typically mild to moderate 1
- Contraindications per FDA label: Screen for history of hypersensitivity reactions 2
If You Actually Mean Bupropion (Not Trileptal):
If the adolescent is on bupropion 150 mg BID for depression or ADHD, this is already the maximum recommended dose (300 mg/day total). Do not increase further. 3
Bupropion Dosing in Adolescents:
- Starting dose: 150 mg once daily
- Maximum dose: 300 mg/day (either 150 mg BID or 300 mg once daily with extended-release formulation)
- Evidence: Studies in adolescents used 150 mg/day or 300 mg/day; doses of 300 mg/day showed better efficacy but 150 mg/day had fewer adverse effects 3
Critical Safety Considerations:
Bupropion is contraindicated in patients with:
- Seizure disorder
- Current or prior bulimia or anorexia nervosa (higher seizure risk) 3
Important Caveats:
- The 2025 ATS guidelines only conditionally recommend bupropion for nicotine cessation in adolescents (very low-certainty evidence) 3
- Bupropion is NOT FDA-approved for tobacco dependence in patients <18 years 3
- For depression/ADHD in adolescents, bupropion is used off-label but has established safety data 4, 5
Please clarify which medication your patient is actually taking to receive accurate dosing guidance.